CoChat
Sign Up
Cited by 122Cancer Genomics and DiagnosticsCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy

Open access
Sivapalan, Lavanya, Murray, Joseph C, Canzoniero, Jenna VanLiere, Landon, Blair, Jackson, Jennifer, Scott, Susan, Lam, Vincent, Levy, Benjamin P. +2 more·2023·Journal for ImmunoTherapy of Cancer
DOI 10.1136/jitc-2022-005924PMC PMC9853269
Open this paper in CoChat — free accountOpen PDF

Abstract

Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor burden dynamics during immunotherapy, the complexity of antitumor immune responses is not fully captured through single-feature ctDNA analyses. This underscores a need for integrative studies modeling the tumor and the immune compartment to understand the kinetics of tumor clearance in association with the quality of antitumor immune responses. Clinical applications of ctDNA testing in patients treated with immune checkpoint inhibitors have shown both predictive and prognostic value through the detection of genomic biomarkers, such as tumor mutational burden and microsatellite instability, as well as allowing for real-time monitoring of circulating tumor burden and the assessment of early on-therapy responses. These efforts highlight the emerging role of liquid biopsies in selecting patients for cancer immunotherapy, monitoring therapeutic efficacy, determining the optimal duration of treatment and ultimately guiding treatment selection and sequencing. The clinical translation of liquid biopsies is propelled by the increasing number of ctDNA-directed interventional clinical trials in the immuno-oncology space, signifying a critical step towards implementation of liquid biopsies in precision immuno-oncology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2022-005924

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 133

  1. [1]Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015– 26. 10.1056/NEJMoa1613683 28212060 PMC5635424 · DOI · Paper page
  2. [2]Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced Nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627– 39. 10.1056/NEJMoa1507643 26412456 PMC5705936 · DOI · Paper page
  3. [3]Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803– 13. 10.1056/NEJMoa1510665 26406148 PMC5719487 · DOI · Paper page
  4. [4]Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521– 32. 10.1056/NEJMoa1503093 25891173 · DOI · Paper page
  5. [5]Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123– 35. 10.1056/NEJMoa1504627 26028407 PMC4681400 · DOI · Paper page
  6. [6]Marcus L, Lemery SJ, Keegan P, et al. Fda approval summary: pembrolizumab for the treatment of microsatellite Instability-High solid tumors. Clin Cancer Res 2019; 25: 3753– 8. 10.1158/1078-0432.CCR-18-4070 30787022 · DOI · Paper page
  7. [7]Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021; 398: 1344– 57. 10.1016/S0140-6736(21)02098-5 34555333 · DOI
  8. [8]Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021; 384: 1191– 203. 10.1056/NEJMoa2032125 33789008 · DOI
  9. [9]Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIb or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. The Lancet 2022; 399: 1718– 29. 10.1016/S0140-6736(22)00562-1 35367007 · DOI
  10. [10]Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 2021; 385: 683– 94. 10.1056/NEJMoa2106391 34407342 · DOI
  11. [11]Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021; 384: 2102– 14. 10.1056/NEJMoa2034442 34077643 PMC8215888 · DOI · Paper page
  12. [16]Schmid P, Cortes J, Dent R, et al. Event-Free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022; 386: 556– 67. 10.1056/NEJMoa2112651 35139274 · DOI · Paper page
  13. [17]Meric-Bernstam F, Larkin J, Tabernero J, et al. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet 2021; 397: 1010– 22. 10.1016/S0140-6736(20)32598-8 33285141 · DOI
  14. [18]Ott PA, Hodi FS, Kaufman HL, et al. Combination immunotherapy: a road map. J Immunother Cancer 2017; 5: 16. 10.1186/s40425-017-0218-5 28239469 PMC5319100 · DOI
  15. [19]Marron TU, Ryan AE, Reddy SM, et al. Considerations for treatment duration in responders to immune checkpoint inhibitors. J Immunother Cancer 2021; 9: e001901. 10.1136/jitc-2020-001901 33653801 PMC7929825 · DOI · Paper page
  16. [20]Anagnostou V, Landon BV, Medina JE, et al. Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. Sci Transl Med 2022; 14: eabo3958. 10.1126/scitranslmed.abo3958 36350985 PMC9844537 · DOI
  17. [21]Anagnostou V, Niknafs N, Marrone K, et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat Cancer 2020; 1: 99– 111. 10.1038/s43018-019-0008-8 32984843 PMC7514475 · DOI
  18. [22]Anagnostou V, Smith KN, Forde PM, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 2017; 7: 264– 76. 10.1158/2159-8290.CD-16-0828 28031159 PMC5733805 · DOI
  19. [23]Anagnostou V, Forde PM, White JR, et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res 2019; 79: 1214– 25. 10.1158/0008-5472.CAN-18-1127 30541742 PMC6432636 · DOI
  20. [25]Stroun M, Lyautey J, Lederrey C, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 2001; 313: 139– 42. 10.1016/s0009-8981(01)00665-9 11694251 · DOI
  21. [26]Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 2017; 9: eaan2415. 10.1126/scitranslmed.aan2415 28814544 PMC6714979 · DOI
  22. [27]Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6: ra24. 10.1126/scitranslmed.3007094 PMC4017867 24553385 · DOI · Paper page
  23. [28]Phallen J, Leal A, Woodward BD, et al. Early noninvasive detection of response to targeted therapy in non-small cell lung cancer. Cancer Res 2019; 79: 1204– 13. 10.1158/0008-5472.CAN-18-1082 30573519 PMC6481620 · DOI
  24. [29]Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 2016; 34: 547– 55. 10.1038/nbt.3520 27018799 PMC4907374 · DOI
  25. [30]Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012; 4: 162ra154. 10.1126/scitranslmed.3004742 PMC3641759 23197571 · DOI
  26. [31]Olsson E, Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 2015; 7: 1034– 47. 10.15252/emmm.201404913 25987569 PMC4551342 · DOI
  27. [32]Shen SY, Singhania R, Fehringer G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature 2018; 563: 579– 83. 10.1038/s41586-018-0703-0 30429608 · DOI · Paper page
  28. [33]Cristiano S, Leal A, Phallen J, et al. Genome-Wide cell-free DNA fragmentation in patients with cancer. Nature 2019; 570: 385– 9. 10.1038/s41586-019-1272-6 31142840 PMC6774252 · DOI · Paper page
  29. [34]Snyder MW, Kircher M, Hill AJ, et al. Cell-Free DNA comprises an in vivo nucleosome footprint that informs its Tissues-Of-Origin. Cell 2016; 164: 57– 68. 10.1016/j.cell.2015.11.050 26771485 PMC4715266 · DOI
  30. [35]Cheung TH, Yim SF, Yu MY, et al. Liquid biopsy of HPV DNA in cervical cancer. J Clin Virol 2019; 114: 32– 6. 10.1016/j.jcv.2019.03.005 30913520 · DOI
  31. [36]Cocuzza CE, Martinelli M, Sina F, et al. Human papillomavirus DNA detection in plasma and cervical samples of women with a recent history of low grade or precancerous cervical dysplasia. PLoS One 2017; 12: e0188592. 10.1371/journal.pone.0188592 29182627 PMC5705130 · DOI
  32. [37]Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14: 985– 90. 10.1038/nm.1789 18670422 PMC2820391 · DOI
  33. [38]Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017; 168: 707– 23. 10.1016/j.cell.2017.01.017 28187290 PMC5391692 · DOI · Paper page
  34. [39]Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 2017; 545: 446– 51. 10.1038/nature22364 28445469 PMC5812436 · DOI
  35. [40]Gremel G, Lee RJ, Girotti MR, et al. Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. Ann Oncol 2016; 27: 1959– 65. 10.1093/annonc/mdw278 27502704 PMC5035787 · DOI
  36. [41]Parikh AR, Leshchiner I, Elagina L, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med 2019; 25: 1415– 21. 10.1038/s41591-019-0561-9 31501609 PMC6741444 · DOI · Paper page
  37. [42]Forde PM, Anagnostou V, Sun Z, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med 2021; 27: 1910– 20. 10.1038/s41591-021-01541-0 34750557 PMC8604731 · DOI
  38. [43]McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351: 1463– 9. 10.1126/science.aaf1490 26940869 PMC4984254 · DOI · Paper page
  39. [44]Jia Q, Chiu L, Wu S, et al. Tracking neoantigens by personalized circulating tumor DNA sequencing during checkpoint blockade immunotherapy in non-small cell lung cancer. Adv Sci 2020; 7: 1903410. 10.1002/advs.201903410 PMC7201246 32382482 · DOI
  40. [45]Hogan SA, Courtier A, Cheng PF, et al. Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunol Res 2019; 7: 77– 85. 10.1158/2326-6066.CIR-18-0136 30425105 · DOI
  41. [46]Valpione S, Galvani E, Tweedy J, et al. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer 2020; 1: 210– 21. 10.1038/s43018-019-0022-x 32110781 PMC7046489 · DOI
  42. [47]Poran A, Scherer J, Bushway ME, et al. Combined TCR repertoire profiles and blood cell phenotypes predict melanoma patient response to personalized neoantigen therapy plus anti-PD-1. Cell Rep Med 2020; 1: 100141. 10.1016/j.xcrm.2020.100141 33294862 PMC7691446 · DOI
  43. [48]Wang X, Muzaffar J, Kirtane K, et al. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J Immunother Cancer 2022; 10: e004512. 10.1136/jitc-2022-004512 35676062 PMC9185557 · DOI
  44. [49]Huang AC, Postow MA, Orlowski RJ, et al. T-Cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017; 545: 60– 5. 10.1038/nature22079 28397821 PMC5554367 · DOI · Paper page
  45. [50]Oliveira G, Stromhaug K, Klaeger S, et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 2021; 596: 119– 25. 10.1038/s41586-021-03704-y 34290406 PMC9187974 · DOI
  46. [52]Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 2017; 377: 2500– 1. 10.1056/NEJMc1713444 29262275 PMC6549688 · DOI · Paper page
  47. [53]Cristescu R, Aurora-Garg D, Albright A, et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer 2022; 10: e003091. 10.1136/jitc-2021-003091 35101941 PMC8804694 · DOI
  48. [54]Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020; 21: 1353– 65. 10.1016/S1470-2045(20)30445-9 32919526 · DOI · Paper page
  49. [55]Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189– 99. 10.1056/NEJMoa1406498 25409260 PMC4315319 · DOI · Paper page
  50. [56]Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124– 8. 10.1126/science.aaa1348 25765070 PMC4993154 · DOI · Paper page
  51. [57]Koeppel F, Blanchard S, Jovelet C, et al. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One 2017; 12: e0188174. 10.1371/journal.pone.0188174 29161279 PMC5697854 · DOI
  52. [58]Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov 2017; 7: 1394– 403. 10.1158/2159-8290.CD-17-0716 28899864 PMC5895851 · DOI
  53. [59]Yang N, Li Y, Liu Z, et al. The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues. BMC Cancer 2018; 18: 319. 10.1186/s12885-018-4199-7 29566644 PMC5865353 · DOI
  54. [60]Gandara DR, Paul SM, Kowanetz M, et al. Blood-Based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med 2018; 24: 1441– 8. 10.1038/s41591-018-0134-3 30082870 · DOI
  55. [61]Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the Mystic phase 3 randomized clinical trial. JAMA Oncol 2020; 6: 661– 74. 10.1001/jamaoncol.2020.0237 32271377 PMC7146551 · DOI · Paper page
  56. [62]Velcheti V, Kim ES, Mekhail T, et al. Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): interim B-F1RST results. Journal of Clinical Oncology 2018; 36: 12001. 10.1200/JCO.2018.36.15_suppl.12001 · DOI
  57. [63]Si H, Kuziora M, Quinn KJ, et al. A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: results from the Mystic study. Clin Cancer Res 2021; 27: 1631– 40. 10.1158/1078-0432.CCR-20-3771 33355200 · DOI
  58. [65]de Castro G, Rizvi NA, Schmid P, et al. NEPTUNE: phase 3 study of first-line Durvalumab plus tremelimumab in patients with metastatic NSCLC. J Thorac Oncol 2022. doi: 10.1016/j.jtho.2022.09.223. [Epub ahead of print: 12 Oct 2022]. 36240972 · DOI
  59. [66]Kim ES, Velcheti V, Mekhail T, et al. Blood-Based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat Med 2022; 28: 939– 45. 10.1038/s41591-022-01754-x 35422531 PMC9117143 · DOI
  60. [67]Dziadziuszko R, Peters S, Gadgeel SM, et al. 1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C. Annals of Oncology 2021; 32: S950– 1. 10.1016/j.annonc.2021.08.1883 · DOI
  61. [68]Peters S, Dziadziuszko R, Morabito A, et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med 2022; 28: 1831– 9. 10.1038/s41591-022-01933-w 35995953 PMC9499854 · DOI
  62. [69]He J, Kalinava N, Doshi P, et al. Abstract 2139: evaluation of tissue- and plasma-derived tumor mutational burden and genomic alterations of interest from the CheckMate 848 clinical trial. Cancer Res 2022; 82: 2139. 10.1158/1538-7445.AM2022-2139 · DOI
  63. [70]Schenker M, Burotto M, Richardet M, et al. Abstract CT022: CheckMate 848: a randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Cancer Res 2022; 82: CT022. 10.1158/1538-7445.AM2022-CT022 PMC11308901 39107131 · DOI
  64. [71]Turajlic S, Litchfield K, Xu H, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol 2017; 18: 1009– 21. 10.1016/S1470-2045(17)30516-8 28694034 · DOI
  65. [72]Montesion M, Murugesan K, Jin DX, et al. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov 2021; 11: 282– 92. 10.1158/2159-8290.CD-20-0672 33127846 · DOI
  66. [73]Nabet BY, Esfahani MS, Moding EJ, et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 2020; 183: 363– 76. 10.1016/j.cell.2020.09.001 33007267 PMC7572899 · DOI
  67. [74]Georgiadis A, Durham JN, Keefer LA, et al. Noninvasive detection of microsatellite instability and high tumor mutation burden in cancer patients treated with PD-1 blockade. Clin Cancer Res 2019; 25: 7024– 34. 10.1158/1078-0432.CCR-19-1372 31506389 PMC6892397 · DOI
  68. [75]Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res 2019; 25: 7035– 45. 10.1158/1078-0432.CCR-19-1324 31383735 · DOI
  69. [76]Le DT, Uram JN, Wang H, et al. Pd-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509– 20. 10.1056/NEJMoa1500596 26028255 PMC4481136 · DOI · Paper page
  70. [77]Buza N, Ziai J, Hui P. Mismatch repair deficiency testing in clinical practice. Expert Rev Mol Diagn 2016; 16: 591– 604. 10.1586/14737159.2016.1156533 26895074 · DOI
  71. [78]Klouch KZ, Stern M-H, Trabelsi-Grati O, et al. Microsatellite instability detection in breast cancer using drop-off droplet digital PCR. Oncogene 2022; 41: 5289– 97. 10.1038/s41388-022-02504-6 36329125 · DOI
  72. [79]Ladas I, Yu F, Leong KW, et al. Enhanced detection of microsatellite instability using pre-PCR elimination of wild-type DNA homo-polymers in tissue and liquid biopsies. Nucleic Acids Res 2018; 46: e74. 10.1093/nar/gky251 29635638 PMC6158611 · DOI
  73. [80]Kasi PM, Klempner SJ, Starr JS, et al. Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI). Journal of Clinical Oncology 2022; 40: 56. 10.1200/JCO.2022.40.4_suppl.056 · DOI
  74. [81]Gray ES, Rizos H, Reid AL, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 2015; 6: 42008– 18. 10.18632/oncotarget.5788 26524482 PMC4747205 · DOI
  75. [83]Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer 2020; 1: 873– 81. 10.1038/s43018-020-0096-5 35121950 · DOI · Paper page
  76. [85]Socinski MA, Paul SM, Yun C, et al. Abstract CT194: exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (PTS) with low circulating tumor DNA (ctDNA) in B-F1RST—a phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC. Cancer Res 2019; 79: CT194. 10.1158/1538-7445.AM2019-CT194 · DOI
  77. [86]Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260– 70. 10.1056/NEJMoa1002315 20525995 · DOI
  78. [87]Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251– 9. 10.1056/NEJMoa0912614 20525993 · DOI
  79. [88]Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375: 1845– 55. 10.1056/NEJMoa1611299 27717298 PMC5648545 · DOI
  80. [89]Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22: 525– 37. 10.1016/S1470-2045(21)00004-8 33721560 PMC8495594 · DOI
  81. [90]Chen K, Zhao H, Shi Y, et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (dynamic). Clin Cancer Res 2019; 25: 7058– 67. 10.1158/1078-0432.CCR-19-1213 31439586 · DOI
  82. [91]Zviran A, Schulman RC, Shah M, et al. Genome-Wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med 2020; 26: 1114– 24. 10.1038/s41591-020-0915-3 32483360 PMC8108131 · DOI
  83. [92]Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 2021; 595: 432– 7. 10.1038/s41586-021-03642-9 34135506 · DOI
  84. [94]Moding EJ, Liu Y, Nabet BY, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer. Nat Cancer 2020; 1: 176– 83. 10.1038/s43018-019-0011-0 34505064 PMC8425388 · DOI
  85. [95]Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022; 386: 2261– 72. 10.1056/NEJMoa2200075 35657320 PMC9701133 · DOI · Paper page
  86. [97]Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent. J Clin Oncol 2022; 40: 567– 75. 10.1200/JCO.21.01929 34985936 PMC8853615 · DOI
  87. [98]Anagnostou V, Yarchoan M, Hansen AR, et al. Immuno-oncology trial endpoints: capturing clinically meaningful activity. Clin Cancer Res 2017; 23: 4959– 69. 10.1158/1078-0432.CCR-16-3065 28864724 PMC5735844 · DOI
  88. [99]Herbreteau G, Langlais A, Greillier L, et al. Circulating tumor DNA as a prognostic determinant in small cell lung cancer patients receiving Atezolizumab. J Clin Med 2020; 9. doi: 10.3390/jcm9123861. [Epub ahead of print: 27 11 2020]. PMC7760916 33261056 · DOI
  89. [100]Váraljai R, Wistuba-Hamprecht K, Seremet T, et al. Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma. JCO Precis Oncol 2020; 3: 1– 10. 10.1200/PO.18.00229 PMC7446476 32914028 · DOI
  90. [101]Seremet T, Jansen Y, Planken S, et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med 2019; 17: 303. 10.1186/s12967-019-2051-8 31488153 PMC6727487 · DOI
  91. [102]Goldberg SB, Narayan A, Kole AJ, et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res 2018; 24: 1872– 80. 10.1158/1078-0432.CCR-17-1341 29330207 PMC5899677 · DOI
  92. [103]Guibert N, Jones G, Beeler JF, et al. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer 2019; 137: 1– 6. 10.1016/j.lungcan.2019.09.005 31518912 · DOI
  93. [104]Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 2018; 24: 1449– 58. 10.1038/s41591-018-0101-z 30013197 · DOI
  94. [105]Keller L, Guibert N, Casanova A, et al. Early circulating tumour DNA variations predict tumour response in melanoma patients treated with immunotherapy. Acta Derm Venereol 2019; 99: 206– 10. 10.2340/00015555-3080 30393817 · DOI
  95. [106]Vega DM, Nishimura KK, Zariffa N, et al. Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. JCO Precis Oncol 2022; 6: e2100372. 10.1200/PO.21.00372 35952319 PMC9384957 · DOI
  96. [107]Burgener JM, Zou J, Zhao Z, et al. Tumor-Naïve multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma. Clin Cancer Res 2021; 27: 4230– 44. 10.1158/1078-0432.CCR-21-0110 34158359 PMC9401560 · DOI
  97. [108]Jacob S, Davis AA, Gerratana L, et al. The use of serial circulating tumor DNA to detect resistance alterations in progressive metastatic breast cancer. Clin Cancer Res 2021; 27: 1361– 70. 10.1158/1078-0432.CCR-20-1566 33323406 · DOI
  98. [109]Hwang M, Canzoniero JV, Rosner S, et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer 2022; 10: e004688. 10.1136/jitc-2022-004688 35688557 PMC9189831 · DOI · Paper page
  99. [110]Leal A, van Grieken NCT, Palsgrove DN, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun 2020; 11: 525. 10.1038/s41467-020-14310-3 31988276 PMC6985115 · DOI
  100. [111]Hellmann MD, Nabet BY, Rizvi H, et al. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clin Cancer Res 2020; 26: 2849– 58. 10.1158/1078-0432.CCR-19-3418 32046999 PMC7299781 · DOI
  101. [112]Lipson EJ, Velculescu VE, Pritchard TS, et al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer 2014; 2: 42. 10.1186/s40425-014-0042-0 25516806 PMC4267741 · DOI
  102. [113]Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov 2020; 10: 1842– 53. 10.1158/2159-8290.CD-20-0047 32816849 PMC8358981 · DOI · Paper page
  103. [114]Lee JH, Long GV, Menzies AM, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with Anti-Programmed cell death 1 antibodies. JAMA Oncol 2018; 4: 717– 21. 10.1001/jamaoncol.2017.5332 29423503 PMC5885201 · DOI
  104. [116]Maluquer C, Bellosillo B, Mussetti A, et al. Liquid biopsy for disease monitoring after anti-CD19 chimeric antigen receptor T cell in diffuse large B-cell lymphoma. EJHaem 2021; 2: 109– 11. 10.1002/jha2.131 35846093 PMC9176123 · DOI
  105. [117]Goodman AM, Holden KA, Jeong A-R, et al. Assessing CAR T-cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-cell lymphomas. Transplant Cell Ther 2022; 28: 30.e1– 30.e7. 10.1016/j.jtct.2021.10.007 34655803 · DOI
  106. [118]Cherng H-JJ, Sun R, Sugg B, et al. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood 2022; 140: 504– 15. 10.1182/blood.2022015601 35512184 PMC9353148 · DOI
  107. [119]Frank MJ, Hossain NM, Bukhari A, et al. Monitoring of circulating tumor DNA improves early relapse detection after Axicabtagene Ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial. J Clin Oncol 2021; 39: 3034– 43. 10.1200/JCO.21.00377 34133196 PMC10166351 · DOI
  108. [120]Mika T, Thomson J, Nilius-Eliliwi V, et al. Quantification of cell-free DNAfor the analysis of CD19-CAR-T cells during lymphoma treatment. Mol Ther Methods Clin Dev 2021; 23: 539– 50. 10.1016/j.omtm.2021.10.009 34853800 PMC8606297 · DOI
  109. [121]Murray JC, Anagnostou V. Translating noninvasive molecular responses into clinical reality for cancer immunotherapy. Nat Rev Clin Oncol 2021; 18: 65– 6. 10.1038/s41571-020-00450-4 33169007 · DOI
  110. [122]Anagnostou V, Ho C, Wheatley-Price P, et al. FP05.02 a Biomarker-Directed, multi-center phase II study of molecular response adaptive Immuno-Chemotherapy in lung cancer. Journal of Thoracic Oncology 2021; 16: S952. 10.1016/j.jtho.2021.08.219 · DOI
  111. [125]Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014; 32: 579– 86. 10.1200/JCO.2012.45.2011 24449238 PMC4820760 · DOI · Paper page
  112. [126]Bauml J, Levy B. Clonal hematopoiesis: a new layer in the liquid biopsy story in lung cancer. Clin Cancer Res 2018; 24: 4352– 4. 10.1158/1078-0432.CCR-18-0969 29748181 · DOI
  113. [127]Warner JL, Jain SK, Levy MA. Integrating cancer genomic data into electronic health records. Genome Med 2016; 8: 113. 10.1186/s13073-016-0371-3 27784327 PMC5081968 · DOI
  114. [130]Mathios D, Johansen JS, Cristiano S, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun 2021; 12: 5060. 10.1038/s41467-021-24994-w 34417454 PMC8379179 · DOI
  115. [131]Jin J, Yang L, Liu D, et al. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis. BMJ Open 2020; 10: e035031. 10.1136/bmjopen-2019-035031 PMC7282333 32499266 · DOI
  116. [132]Douville C, Springer S, Kinde I, et al. Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (lines). Proc Natl Acad Sci U S A 2018; 115: 1871– 6. 10.1073/pnas.1717846115 29432176 PMC5828610 · DOI
  117. [133]Kirkizlar E, Zimmermann B, Constantin T, et al. Detection of clonal and Subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology. Transl Oncol 2015; 8: 407– 16. 10.1016/j.tranon.2015.08.004 26500031 PMC4631096 · DOI
  118. [134]Medina JE, Roussos Torres ET, Leal A, et al. 1669P monitoring immune checkpoint inhibition in advanced solid tumors using genome-wide cfDNA fragmentomes. Annals of Oncology 2022; 33: S1306– 7. 10.1016/j.annonc.2022.07.1749 · DOI
  119. [135]Ivanov M, Baranova A, Butler T, et al. Non-Random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation. BMC Genomics 2015; 16 Suppl 13: S1. 10.1186/1471-2164-16-S13-S1 PMC4686799 26693644 · DOI
  120. [136]Ulz P, Thallinger GG, Auer M, et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet 2016; 48: 1273– 8. 10.1038/ng.3648 27571261 · DOI
  121. [137]Poore GD, Kopylova E, Zhu Q, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature 2020; 579: 567– 74. 10.1038/s41586-020-2095-1 32214244 PMC7500457 · DOI · Paper page
  122. [138]Godsey JH, Silvestro A, Barrett JC, et al. Generic protocols for the analytical validation of next-generation sequencing-based ctDNA assays: a joint consensus recommendation of the BloodPAC's analytical variables Working group. Clin Chem 2020; 66: 1156– 66. 10.1093/clinchem/hvaa164 32870995 PMC7462123 · DOI · Paper page
  123. [139]Williams PM, Forbes T, P Lund S, et al. Validation of ctDNA quality control materials through a Precompetitive collaboration of the foundation for the National Institutes of health. JCO Precis Oncol 2021; 5: 910– 20. 10.1200/PO.20.00528 PMC8232894 34250423 · DOI
  124. [140]Pascual J, Attard G, Bidard F-C, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine Working group. Ann Oncol 2022; 33: 750– 68. 10.1016/j.annonc.2022.05.520 35809752 · DOI · Paper page
  125. [141]Chakravarty D, Johnson A, Sklar J, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. J Clin Oncol 2022; 40: 1231– 58. 10.1200/JCO.21.02767 35175857 · DOI
  126. [142]Krebs MG, Malapelle U, André F, et al. Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review. JAMA Oncol 2022; 8: 1830. 10.1001/jamaoncol.2022.4457 36264554 · DOI
  127. [143]Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International association for the study of lung cancer. J Thorac Oncol 2021; 16: 1647– 62. 10.1016/j.jtho.2021.06.017 34246791 · DOI · Paper page
  128. [145]Khagi Y, Goodman AM, Daniels GA, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res 2017; 23: 5729– 36. 10.1158/1078-0432.CCR-17-1439 28972084 PMC5678984 · DOI
  129. [146]Wang Z, Duan J, Cai S, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol 2019; 5: 696– 702. 10.1001/jamaoncol.2018.7098 30816954 PMC6512308 · DOI · Paper page
  130. [147]Peters S, Spigel D, Ahn M, et al. P03.03 MERMAID-1: a phase III study of adjuvant Durvalumab plus chemotherapy in resected NSCLC patients with MRD+ post-surgery. Journal of Thoracic Oncology 2021; 16: S258– 9. 10.1016/j.jtho.2021.01.376 · DOI
  131. [148]Spigel DR, Peters S, Ahn M-J, et al. 93TiP MERMAID-2: phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy. Journal of Thoracic Oncology 2021; 16: S745– 6. 10.1016/S1556-0864(21)01935-3 · DOI
  132. [149]TSK M, Gadgeel S, Kim ES. Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC. Annals of Oncology 2017; 28.
  133. [150]Lee R, Rothwell DG, Chow S, et al. Cactus: a parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma. JCO 2021; 39: TPS9587. 10.1200/JCO.2021.39.15_suppl.TPS9587 · DOI

Cited by

Sorted by citations

Authors
Sivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V.
Affiliations
  • Johns Hopkins University (US)
  • Personal Genome Diagnostics, Baltimore, Maryland, USA
Corresponding author
Anagnostou, Valsamo
ORCID
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2023-01
Volume
11
Issue
1
Pages
e005924
ISSN
2051-1426 (ISSN-L)
DOI
10.1136/jitc-2022-005924
PMC
PMC9853269
OpenAlex
W4317434397
Cited by
122
References
8
Citations by year
2026: 26 · 2025: 43 · 2024: 33 · 2023: 20
FWCI
3.85
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Defense (CA190755)
  • International Lung Cancer Foundation (N/A)
  • Emerson Collective (N/A)
  • National Institutes of Health (CA121113)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
liquid biopsy, circulating tumor DNA, cancer immunotherapy, immune checkpoint inhibitors, tumor burden monitoring, clonal evolution, tumor mutational burden, microsatellite instability, predictive biomarkers, prognostic factors, antitumor immunity, precision immuno-oncology, treatment response monitoring
MeSH terms
Liquid Biopsy, Circulating Tumor DNA, Humans, Immunotherapy, Neoplasms, Prognosis, Biomarkers, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review